Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).

• Status: TERMINATED
• Trial end date: 2024-07-31

Summary

The purpose of the study is to assess drug-drug interaction (DDI) and safety of AZD4041 and itraconazole in healthy participants (Part 1), and to assess efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD404 when administered with buprenorphine/buprenorphine + naloxone in participants with moderate to severe opioid use disorder (OUD)

• Phase: PHASE1

Details

• Lead Sponsor: AstraZeneca
• Collaborator: Parexel
• Treatments: Buprenorphine; Buprenorphine, Naloxone Drug Combination; Hydromorphone; Itraconazole